Brazil approves Dengvaxia treatment for use
According to Sanofi Pasteur, approximately 1.4 million people in Brazil have been affected by the current dengue outbreak. The Brazilian health surveillance agency, known as ANVISA, allows the vaccine to be used for individuals between nine and 45 years of age. Approximately 70 percent of dengue patients this year were nine and older.
"This new approval of Dengvaxia by the ANVISA, a well-recognized and World Health Organization (WHO)-certified regulatory authority is an important milestone for Sanofi Pasteur," Guillaume Leroy, vice president of dengue vaccine development for Sanofi Pasteur, said." Dengvaxia has the potential to significantly reduce the dengue disease burden and to help Brazil reach the WHO's 2020 dengue reduction objectives."
Dengue fever is considered to be a public health concern in tropical and subtropical regions of Latin America and Asia. The WHO reports that there are approximately 400 million dengue infections on an annual average.
This vaccine has been able to prevent dengue hospitalization in approximately 80 percent of cases and protect patients from more severe forms approximately 93 percent of the time.